Natural allelic variants of bovine ATP-binding cassette transporter ABCG2: Increased activity of the Ser581 variant and development of tools for the discovery of new ABCG2 inhibitors

Drug Metabolism and Disposition

Volumn 37, Issue 1, 2009, Pages 5-9

  Merino, Gracia ^a   Real, Rebeca ^a   Baro, Marta F ^a   Gonzalez Lobato, Lucia ^a   Prieto, Julio G ^a   Alvarez, Ana I ^a   Marques, Margarita M ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DRUG RESIDUE; GENISTEIN; IVERMECTIN; KO 143; LACTONE DERIVATIVE; MITOXANTRONE; PROTEIN INHIBITOR; SELAMECTIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COW; DAIRY INDUSTRY; DRUG ELIMINATION; FIBROBLAST; GENETIC VARIABILITY; MAMMARY GLAND; MILK; NONHUMAN; NUCLEOTIDE SEQUENCE; POLLUTANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ALLELES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CATTLE; DAIRYING; DRUG DISCOVERY; POLYMORPHISM, SINGLE NUCLEOTIDE; SERINE;

BOVINAE; MURINAE; OVIS;

EID: 58149469242     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022715     Document Type: Article

References (29)

1. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, and Schinkel AH (2002) Potent and specific inhibition of the breast cancer
2. resistance protein multidurg transporter in vitro and in mouse intestine by a novel analogue of furnitremorgin C. Mol Cancer Ther 1:417-425.
3. Alvarez L. Lifschitz A, Entrocasso C, Manazza J, Mottier L, Borda B, Virkel G, and Lanusse C (2008) Evaluation of the interaction between ivermectin and albendazole following their combined use in lambs. J Vet Pharmacol Ther 31:230-239.
4. Bards ley WG (2001) SIMFTT. Simulation, fitting, statistics and plotting. Version 5.4. Reference Manual, University of Manchester, Manchester.
5. Brayden DJ and Griffin J (2008) Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers. Vet Res Commun 32:93-106.
6. Clark R, Kerr ID, and Callaghan R (2006) Multiple drug binding sites on the R482G isoform of the ABCG2 transporter. Br J Pharmacol 149:506-515.
7. Cohen-Zinder M, Seroussi E, Larkin DM, Loor JJ, Everts-van der Wind A, Lee JH, Drackley JK, Band MR, Hernandez AG, Shani M, et al. (2005) Identification of a missense mutation in the bovine ABCG2 gene with a major effect on the QTL on chromosome 6 affecting milk yield and composition in Holstein cattle. Genome Res 15:936-944.
8. Griffin J, Fletcher N, Clemence R, Blanchflower S, and Brayden DJ (2005) Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. J Vet Pharmacol Ther 28:257-265.
9. Hard wick LJ, Velamakanni S, and van Veen HW (2007) The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br J Pharmacol 151:163-174.
10. Imai Y, Tsukahara S, Asada S, and Sugimoto Y (2004) Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64:4346-4352.
11. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, and Schinkel AH (2005) The breast cancer resistance protein (BCRPJABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127-129.
12. Marques MM, Thomson AJ, McCreath KJ, and McWhir J (2006) Conventional gene targeting protocols lead to loss of targeted cells when applied to a silent gene locus in primary fibroblasts. J Biotechnol 125:185-193.
13. Merino G, Molina AJ, Garcia JL, Pulido MM, Prieto JG, and Alvarez AI (2003) Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. Int J Pharm 263:123-132.
14. Merino G, Jonker JW, Wagenaar E, Pulido MM, Molina AJ, Alvarez AI, and Schinkel AH (2005) Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos 33:614-618.
15. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, and Prieto JG (2006) Breast cancer resistance protein (BCRPJABCG2) transports fluoroquinolone antibiotics and affects their oral availability pharmacokinetics and milk secretion. Drug Metab Dispos 34:690-695.
16. Mizuarai S, Aozasa N, and Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109:238-246.
17. Morris ME and Zhang S (2006) Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 78:2116-2130.
18. +/peptide cotransporter in rat digestive tract. Biochem Biophys Res Commun 220:848-852.
19. Olsen HG, Nilsen H, Hayes B, Berg PR, Svendsen M, Lien S, and Meuwissen T (2007) Genetic support for a quantitative trait nucleotide in the ABCG2 gene affecting milk composition of dairy cattle. BMC Genet 8:32.
20. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, and Schinkel AH (2005) Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-l-methyl-6- phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312:144-152.
21. Pulido MM, Molina AJ, Merino G, Prieto JG, and Alvarez AI (2006) Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther 29:279-287.
22. Shukla S, Wu CP, Nandigama K, and Ambudkar SV (2007) The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther 6:3279-3286.
23. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, and McLeod HL (2004) Diflomotecan pharmacokinetic in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 76:38-44.
24. van Herwaarden AE and Schinkel AH (2006) The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci 27:10-16.
25. van Herwaarden AE, Wagenaar E, Merino G, Jonker JW, Rosing H, Beijnen JH, and Schinkel AH (2007) Multidrug transporter ABCG2Jbreast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol 27:1247-1253.
26. Vethanayagam RR, Wang H, Gupta A, Zhang Y, Lewis F, Unadkat JD, and Mao Q (2005) Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N. Drug Metab Dispos 33:697-705.
27. Wang X and Morris ME (2007) Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos 35:268-274.
28. Wu HJ, Luo J, Wu N, Matand K, Zhang LJ, Han XF, and Yang BJ (2008) Cloning, sequence and functional analysis of goat ATP-binding cassette transporter G2 (ABCG2). Mol Biotechnol 39:21-27.
29. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, et al. (2008) Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Mol Ther 84:95-103.